Ganga Pharmaceuticals share price

BSE: 539680Pharmaceuticals & Biotechnology

Ganga Pharmaceuticals Limited · Face value ₹10 · Listed Feb 2016

Last traded ₹12.50 on 8 Sep 2026

Latest announcements

Routine notices left out.

Share price history

Daily closes since Feb 2016, adjusted for splits and bonuses

Daily close, ₹ per share

Results for the half year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

Revenue
₹1.46 Cr+10.2% on a year ago · +6.9% on the half year before
Net profit
₹0.08 Cr+39.5% on a year ago · +209.3% on the half year before
Earnings per share
₹0.13+18.2% on a year ago · +225.0% on the half year before
Net margin
5.2%

From revenue to net profit, ₹ crore

  1. Revenue1.5
  2. Other income+0.1
  3. Finance costs−0.1
  4. Profit before tax0.1
  5. Tax0.0
  6. Net profit0.1

Ganga Pharmaceuticals results by half year

Standalone: the listed company alone, without its subsidiaries. Latest half year to Mar 2026. Results for the half year to Sep 2026 are due by 14 Nov 2026, 45 days after it ends. Every company's dates are on the results calendar.

Revenue and net profit by half year, ₹ crore

  • Revenue
  • Net profit
1.30.0Sep 231.40.0Mar 241.30.0Sep 241.30.1Mar 251.40.0Sep 251.50.1Mar 26
Peak revenue ₹1.46 Cr, half year to Mar 2026; lowest ₹1.31 Cr, half year to Sep 2024

Operating and net margin by half year, per cent

  • Operating margin
  • Net margin
5.2%−8.6%4.0%−8.6%−1.7%1.2%2.1%1.8%4.1%1.8%5.2%Sep 23Mar 24Sep 24Mar 25Sep 25Mar 26
₹ croreSep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Filed 7 NovMar 2026Filed 21 May
Revenue from operations1.251.241.351.231.321.421.311.331.371.46
1.22–1.28–1.27–1.42–1.39–
Materials and goods bought0.590.690.620.620.620.620.620.600.630.68
Employee costs0.25–0.26–0.25–0.29–0.32–
Other expenses0.38–0.40–0.39–0.52–0.44–
Operating profit before depreciation0.03–0.07–0.05–−0.11–−0.02–
Operating margin2.3%–5.5%–4.0%–−8.6%–−1.7%–
Depreciation and amortisation0.03–0.03–0.03–0.02–0.03–
Other income0.110.150.120.180.090.150.290.140.150.13
Finance costs0.100.090.120.070.090.090.090.090.070.07
Profit before tax0.010.040.040.010.020.040.070.030.030.10
0.000.010.010.000.000.010.04−0.030.010.02
Tax rate26.0%26.0%26.2%26.1%13.3%31.8%64.2%−100.0%26.0%19.9%
Net profit0.000.030.030.010.020.030.020.060.020.08
Net margin0.4%2.7%2.3%0.6%1.2%2.1%1.8%4.1%1.8%5.2%
Earnings per share₹0.01₹0.08₹0.08₹0.02₹0.04₹0.07₹0.05₹0.11₹0.04₹0.13
Diluted earnings per share₹0.01₹0.08₹0.08₹0.02₹0.04₹0.03₹0.05₹0.07₹0.04₹0.13
Earnings per share in rupees, restated for later splits and bonuses.

10 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
3.00.1Mar 173.10.1Mar 183.40.21.9Mar 193.10.21.5Mar 202.40.01.6Mar 212.50.01.8Mar 222.60.01.7Mar 232.70.01.4Mar 242.60.11.4Mar 252.80.11.1Mar 26
Peak revenue ₹3.36 Cr, year to Mar 2019; lowest ₹2.37 Cr, year to Mar 2021

Operating and net margin, per cent

  • Operating margin
  • Net margin
10.4%−4.4%10.2%10.4%1.7%0.2%2.1%−4.4%1.4%2.5%3.1%5.6%6.1%0.9%1.5%1.5%1.7%3.0%3.6%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue2.8
  2. Materials and goods−1.3
  3. Employee costs−0.6
  4. Other expenses−0.9
  5. Operating profit0.0
  6. Depreciation−0.1
  7. Other income+0.3
  8. Finance costs−0.1
  9. Profit before tax0.1
  10. Tax0.0
  11. Net profit0.1

What the company owns

  • Plant, investments and other assets₹5 Cr
  • Cash and bank₹3 Cr
  • Inventory₹1 Cr
  • Receivables₹1 Cr

What pays for it: net worth and liabilities

  • Net worth₹8 Cr
  • Borrowings₹1 Cr
  • Other liabilities₹0 Cr
  • Owed to suppliers₹0 Cr

Profit and loss

Standalone, ₹ crore, years to March.

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 21 May
Revenue from operations3.013.053.363.082.372.492.592.742.642.83
2.702.74–––2.452.582.682.752.79
Materials and goods bought1.041.161.231.281.241.281.241.251.211.30
Employee costs0.33––––0.430.510.580.580.59
Other expenses1.31––––0.740.830.850.960.90
Operating profit before depreciation0.310.32–––0.040.000.06−0.120.04
Operating margin10.2%10.4%–––1.7%0.2%2.1%−4.4%1.4%
Materials, % of revenue34.6%––––51.3%47.9%45.5%46.1%46.1%
Employee costs, % of revenue11.1%––––17.5%19.8%21.2%21.9%20.8%
Other expenses, % of revenue43.4%––––29.6%32.1%31.2%36.5%31.7%
Depreciation and amortisation0.040.06–––0.050.060.050.050.06
Operating profit after depreciation0.270.26–––−0.01−0.050.01−0.16−0.02
Other income0.160.150.140.170.250.260.300.240.440.28
Finance costs0.320.280.250.240.190.190.190.180.180.13
Profit before tax0.110.130.260.260.040.050.050.060.090.13
0.030.030.070.070.020.010.010.020.020.03
Net profit0.070.090.190.190.020.040.040.050.080.10
Net margin2.5%3.1%5.6%6.1%0.9%1.5%1.5%1.7%3.0%3.6%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the year to Mar 2018 they do not, so they are left blank. Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the years to Mar 2019, Mar 2020 and Mar 2021: the statement does not state its depreciation, which operating profit is worked out from, so operating profit is not given.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 21 May
5.155.355.375.415.457.057.138.31
Share capital4.064.064.064.064.06––5.91
Reserves1.091.291.311.351.39––2.40
1.871.451.561.811.661.361.421.09
1.941.621.611.691.891.201.601.24
0.660.600.680.900.640.400.240.10
Total assets7.767.577.668.007.988.658.979.65
3.413.153.073.092.842.902.112.08
4.354.424.594.915.155.756.877.56
Net debt1.641.441.541.791.631.331.12−1.89
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 21 May
−0.18−0.21−0.04−1.26−0.58−1.31
−0.17−0.20−0.02−1.25−0.56−1.28
−0.18−0.23−0.02−1.30−0.44−1.31
Receivables0.25−0.070.00−0.030.01−0.03
Inventories−0.09−0.02−0.03−0.060.060.02
Payables−0.120.090.06−0.480.18−0.16
Other working capital−0.22−0.23−0.05−0.73−0.69−1.14
Tax paid−0.01−0.01−0.02−0.02−0.02−0.03
Capital spending0.020.010.010.020.000.04
Free cash flow−0.19−0.23−0.05−1.29−0.58−1.35
0.280.190.490.131.180.24
−0.100.03−0.441.14−0.330.82
Dividends paid0.000.000.000.000.000.00
Shares issued0.000.000.001.560.001.08
Net change in cash0.000.010.010.000.27−0.24
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 21 May
Earnings per share₹0.18₹0.23₹0.46₹0.47₹0.05₹0.09₹0.10₹0.11₹0.16₹0.17
Diluted earnings per share₹0.18₹0.23₹0.46₹0.47₹0.05₹0.09₹0.10₹0.07₹0.12₹0.17
Book value per share––₹12.69₹13.18₹13.23₹13.32₹13.42₹17.36₹14.75₹14.06
Shareholder yield–––––0.0%––0.0%–
Market cap at the year end (₹ crore)3.342.73–2.86–4.16––4.92–

Ratios

Standalone, years to March.

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 21 May
Revenue growth6.1%1.4%10.1%−8.4%−22.9%4.8%3.9%5.8%−3.6%7.2%
Operating profit growth–3.0%––––−88.8%1,125.1%––
Net profit growth54.2%27.0%99.0%1.0%−89.1%84.9%3.6%18.6%69.5%28.5%
Earnings per share growth12.5%27.8%100.0%2.2%−89.4%80.0%7.8%13.4%45.5%6.3%
––3.6%3.6%0.4%0.7%0.7%0.7%1.1%1.3%
–––0.0 pts−3.2 pts0.3 pts0.0 pts0.0 pts0.4 pts0.2 pts
From the net margin–––0.4 pts−3.1 pts0.3 pts0.0 pts0.1 pts0.6 pts0.2 pts
From asset turnover–––−0.3 pts−0.1 pts0.0 pts0.0 pts0.0 pts−0.1 pts0.0 pts
From borrowing–––−0.1 pts0.0 pts0.0 pts0.0 pts−0.1 pts−0.1 pts0.0 pts
Return on capital employed–––––−0.2%−0.7%0.1%−1.9%−0.2%
Cash conversion––––−856.1%−555.9%−101.5%−2,712.4%−730.6%−1,291.3%
Interest cover0.80.9–––––0.0––
Debt to equity––0.360.270.290.330.310.190.200.13
Receivable days––133127126131125123126121
Inventory days––341297334329348364355326
Payable days––––––––8333
Cash conversion cycle, days––––––––398414
Working capital days––367433592605600732851560
Asset turnover––0.430.400.310.320.320.330.300.30
Assets per rupee of net worth––1.511.461.421.451.471.331.241.21
Sales per rupee of plant––4.194.063.293.664.044.473.974.38
Capital spending to depreciation–––––0.270.260.450.000.66
Interest cover is left blank for the years to Mar 2022, Mar 2023, Mar 2025 and Mar 2026: operating profit after depreciation is a loss, and a loss covers no interest bill. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
1.1%
Cash from operations against operating profit
−3,352.2%
Measure10 years5 years3 years
Revenue growth, yearly rate0.0%3.6%3.0%
Profit growth, yearly rate7.8%37.7%37.2%
Return on equity, average–0.9%1.1%
Return on capital employed, average–−0.6%−0.7%
Operating margin, average–0.2%−0.3%
Net margin, average2.9%2.3%2.8%
Asset turnover, average–0.310.31
Cash conversion cycle, days, average––406
Debt to equity, average–0.230.17

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations−3.40−3.15−1.31
Cash from investing2.241.550.24
Cash from financing1.211.630.82
Capital spending0.090.060.04
Dividends paid0.000.000.00
Shares issued for cash2.642.641.08
Borrowings raised––0.00
Borrowings repaid0.850.370.13

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Receivables growth less revenue growthOur threshold 0 percentage points–––−4.27−0.563.97−4.20−1.962.23−4.10
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––−13.3912.15−1.705.744.43−2.27−8.73
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––18.2913.679.057.7518.6334.72−70.54
Effective tax ratePublished threshold 17.16 per cent30.1925.9827.5926.0145.3325.9826.0326.3816.5821.50
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––−0.47−4.39−0.470.74−1.93
A threshold marked as ours has no published figure; it is the line we read the check against.

Business segments

In the year to Mar 2026 the company reports one business segment, Pharmaceuticals products, which carries all its revenue.

Who owns Ganga Pharmaceuticals, filing by filing

Per cent of the company's shares. The last ten years of filings, from Dec 2016; the latest is the filing of 30 Sep 2026.

30 Sep 2026 filing

  • Promoters50.91%
  • Individuals and others49.09%
Per centDec 2016Jun 2017Dec 2017Jun 2018Sep 2018Dec 2018Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Jun 2022Sep 202630 Sep
66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%50.91%
Indian promoters66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%66.71%50.91%
33.29%33.29%33.29%33.29%33.29%33.29%33.29%33.29%33.29%33.29%33.29%33.29%33.29%33.29%33.29%33.29%33.29%49.09%
Shares in issue40,61,50040,61,50040,61,50040,61,50040,61,50040,61,50040,61,50040,61,50040,61,50040,61,50040,61,50040,61,50040,61,50040,61,50040,61,50040,61,50040,61,50059,11,500
Shares locked in29,81,50014,15,4508,74,5508,74,5508,74,5508,74,550–––––––––––3,00,000
Promoters' shares locked in27,09,55012,24,0508,74,5508,74,5508,74,5508,74,550–––––––––––3,00,000
Filings before Sep 2026 are on an older form, which did not split institutions into foreign and Indian and grouped some holders differently, so those columns show only the lines both forms state alike. A dash is a line the filing did not state.

Number of Ganga Pharmaceuticals shareholders

Shareholders on the company's register in each filing.

Shareholders, filing by filing

369Dec 16361Jun 17357Dec 17353Jun 18353Sep 18349Dec 18353Jun 19353Sep 19351Dec 19353Mar 20354Jun 20355Dec 20354Mar 21354Jun 21354Sep 21354Dec 21356Jun 22364Sep 26
ShareholdersDec 2016Jun 2017Dec 2017Jun 2018Sep 2018Dec 2018Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Jun 2022Sep 202630 Sep
All shareholders369361357353353349353353351353354355354354354354356364
999999999999999998
Indian promoters999999999999999998
360352348344344340344344342344345346345345345345347356
Filings before Sep 2026 are on an older form, which did not split institutions into foreign and Indian and grouped some holders differently, so those columns show only the lines both forms state alike. A dash is a line the filing did not state.

Ganga Pharmaceuticals promoters

Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing of 30 Sep 2026; the largest is SHARMA BHARAT B, 24.64%.

Holder
SHARMA BHARAT BIndividuals and Hindu undivided families24.64%14,56,5850.00%
SRIJNA SHARMAIndividuals and Hindu undivided families7.48%4,41,90545.26%
ANAGH BHARAT SHARMAIndividuals and Hindu undivided families6.09%3,60,00027.78%
BRIJMOHAN SHARMA HUF .Individuals and Hindu undivided families5.91%3,49,5000.00%
BHARAT BRIJMOHAN SHARMA HUF SHARMAIndividuals and Hindu undivided families3.21%1,90,0000.00%
USHA SHUKLAIndividuals and Hindu undivided families1.61%95,1100.00%
AMIT SHUKLAIndividuals and Hindu undivided families1.29%76,4500.00%
ANKITA AMIT SHUKLAIndividuals and Hindu undivided families0.68%40,0000.00%
No promoter shares are reported as pledged. Locked in is the share of the holder's own shares that cannot be sold yet, as after a listing or an allotment.

Largest public holders of Ganga Pharmaceuticals, filing by filing

Per cent, on the same shares as the split above.

HolderDec 2016Jun 2017Dec 2017Jun 2018Sep 2018Dec 2018Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Jun 2022Sep 202630 Sep
BHAVESH DHIRAJLAL TANNAResident individuals, over ₹2 lakh at face value–––––––––––––––––6.61%
LENUS FINVEST PRIVATE LIMITEDCompanies–––––––––––––––––6.34%
PLUTUS CAPITAL MANAGEMENT LLP .Companies–––––––––––––––––6.34%
PRAKASH DHIRAJLAL TANNAResident individuals, over ₹2 lakh at face value–––––––––––––––––5.50%
NIRANJAN KUMAR GOELResident individuals, over ₹2 lakh at face value––––––––––––––––3.55%2.44%
SANJAY DHANSUKHLAL SHAHResident individuals, over ₹2 lakh at face value1.97%1.97%1.97%1.97%1.97%1.97%1.97%1.97%1.97%1.97%1.97%1.97%1.97%1.97%1.97%1.97%1.97%1.22%
AKSHAY AMARNATH SHARMA .Resident individuals, over ₹2 lakh at face value–––––––––1.77%1.77%2.17%2.17%2.17%2.17%2.17%1.77%1.22%
RAMESHCHAND RAWATMAL AGARWALResident individuals, over ₹2 lakh at face value––––––1.38%1.38%1.38%1.38%1.38%1.38%1.38%1.38%1.38%1.38%1.38%–
NIRAJ RAMESHCHANDRA AGARWALResident individuals, over ₹2 lakh at face value–––––––––––1.38%1.38%1.38%1.38%1.38%1.38%–
ANJU RITESH AGARWALResident individuals, over ₹2 lakh at face value––––––1.18%1.18%1.18%1.18%1.18%1.18%1.18%1.18%1.18%1.18%1.18%–
KIRAN AMARNATH SHARMAResident individuals, over ₹2 lakh at face value–––––––––1.18%1.18%1.18%1.18%1.18%1.18%1.18%1.18%–
BABALBHAI MANILAL PATELResident individuals, over ₹2 lakh at face value–2.36%3.74%3.74%3.74%3.74%3.55%3.55%3.55%3.35%3.35%3.35%3.35%3.35%3.35%3.35%––
NIRAJ AGARWALResident individuals, over ₹2 lakh at face value––––––1.38%1.38%1.38%1.38%1.38%–––––––
SHWETA AKASH SHARMAResident individuals, over ₹2 lakh at face value–––––––––1.38%1.38%–––––––
OVERSKUD MULTI ASSET MANAGEMENT PRIVATE LIMITEDOther non-institutions5.12%4.14%4.14%4.14%4.14%4.14%4.14%4.14%4.14%–––––––––
SAJANKUMAR RAMESHWARLAL BAJAJResident individuals, over ₹2 lakh at face value4.73%4.73%4.73%4.73%4.73%4.73%––––––––––––
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. A dash is a filing that did not name the holder, which includes holding under one per cent.

Ganga Pharmaceuticals share price by year

Each calendar year to 2025.

YearClose at year endChangeHighest closeLowest close
202511.68−37.3%17.599.25
202418.62−34.6%27.1015.00
202328.49+193.7%28.498.10
20229.70+94.0%15.795.50
20215.00−45.1%7.505.00
20209.10+1.1%12.007.05
20199.00+60.7%9.006.00
20185.60−20.0%6.735.49
20177.00−6.7%9.475.83
20167.50–14.507.10
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2021 is from its first session, 2 Feb 2021. 2020 is from its first session, 12 Feb 2020. 2018 is from its first session, 27 Feb 2018. 2016 is from its first session, 22 Feb 2016. The close is the year's last trade for 2025 (20 Nov 2025), 2024 (13 Dec 2024), 2022 (10 Nov 2022), 2021 (22 Sep 2021), 2020 (17 Dec 2020), 2019 (18 Dec 2019), 2018 (13 Dec 2018) and 2016 (13 Dec 2016).

Recent sessions

The 10 trading days to 8 Sep 2026, as traded on BSE.

DateOpenHighLowCloseAverage priceVolume
8 Sep 202612.0012.5012.0012.5012.2516,000
12 Feb 202612.0012.0012.0012.0012.008,000
23 Jan 202612.0012.0012.0012.0012.0016,000
22 Jan 202613.9713.9713.9713.9713.978,000
21 Jan 20269.3511.809.3511.809.9832,000
20 Nov 202511.6811.6811.6811.6811.688,000
3 Sep 202514.6014.6014.6014.6014.608,000
22 Jul 202514.6014.6014.6014.6014.608,000
23 May 202513.3213.3213.3213.3213.3216,000
22 May 202512.1614.8012.1614.8013.0424,000
Prices in ₹ per share as traded, not adjusted.

Price adjustments

What the price chart is corrected for, so it reads as one share held throughout.

Ex-dateEventPrice factorWhat happened
20 Nov 2025Price move–Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for.
16 Aug 2024Price move–Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for.
21 Sep 2023Price move–Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for.
29 Aug 2023Price move–Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for.
1 Aug 2023Price move–Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for.
13 Jun 2023Price move–Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for.
5 Jul 2021Price move–Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for.
Each event is noted and not adjusted for.

Company details

BSE code
539680
ISIN
INE615T01017
Industry
Pharmaceuticals & Biotechnology
CIN
L99999MH1989PLC053392
Corporate identity number, the registrar of companies' code for it
Incorporated
1989
Registered office
Gangatat, Dhanvantri Marg, Gopcharpada, Virar (E), Palghar 401305, Maharashtra
Share registrar
KFin Technologies Ltd
Keeps the register of shareholders and handles transfers and dividend payments